What is Epitel?
Epitel is a specialized digital health enterprise focused on the development of wearable, wireless EEG monitoring solutions. The company's flagship product, REMI, received FDA clearance in 2021, marking a significant milestone for its application in hospital emergency rooms and critical care units. By providing accessible, affordable, and reliable seizure detection, Epitel addresses a critical gap in neurological diagnostics. The company operates at the intersection of medical technology and data-driven patient care, aiming to improve clinical outcomes through continuous, real-time monitoring capabilities that were previously restricted by cumbersome, traditional equipment.
How much funding has Epitel raised?
Epitel has raised a total of $38.6M across 3 funding rounds:
Debt
$98K
Series A
$12.5M
Series B
$26M
Debt (2021): $98K with participation from PPP
Series A (2022): $12.5M led by Genoa Ventures, OSF Ventures, Dexcom, Medmountain Ventures, Catalyst Health Ventures, Wavemaker Three-Sixty Health, and Salt Lake City Angels
Series B (2026): $26M supported by Catalyst Health Ventures and Genoa Ventures
Key Investors in Epitel
Genoa Ventures
Genoa Ventures is an investment firm focused on early-stage companies that are innovating at the intersection of biology and technology, aiming to empower category-defining firms.
Catalyst Health Ventures
Catalyst Health Ventures is a venture capital firm focused on investing in transformative medical technologies that address global unmet healthcare needs through strategic insight and mentorship.
OSF Ventures
Osf Ventures LLC is a venture capital and private equity firm that provides strategic backing to innovative healthcare companies.
What's next for Epitel?
With the successful closure of its latest financing round, Epitel is poised to scale its commercial operations and deepen its market penetration. The strategic focus will likely shift toward expanding the utility of its EEG platform beyond the emergency room, potentially targeting outpatient settings and long-term monitoring markets. By leveraging the expertise of its high-profile investor syndicate, the company is well-positioned to navigate the complexities of the medical device regulatory landscape while maintaining its competitive edge in the digital health sector. Future growth will be defined by the company's ability to integrate its diagnostic data into broader clinical decision-support systems, thereby enhancing its value proposition to healthcare providers and hospital networks globally.
See full Epitel company page
